Pharming Adds CDZ173 To Its Rare Disease Pipeline, Foresees Launch by 2022
The Dutch rare disease group says licensing CDZ173 from Novartis is Pharming’s first step towards building off the commercial success of its sole product, Ruconest, in HAE.
You may also be interested in...
The Dutch firm’s US filing for its first-in-class PI3K inhibitor has been accepted under priority review, bringing the asset closer to becoming the first disease-modifying option for a rare, genetic disorder.
The Dutch firm has announced its intention to submit US and EU filings for leniolisib and expand development into Japan after the candidate impressed in an ultra-rare disease study.
Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.